Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants.

[1]  M. Prins,et al.  Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism , 2017, The New England journal of medicine.

[2]  P. Prandoni,et al.  Inter-observer variability of compression ultrasound for the assessment of residual vein thrombosis. , 2016, Thrombosis research.

[3]  M. Prins,et al.  Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis , 2016, Thrombosis and Haemostasis.

[4]  M. Prins,et al.  Post-thrombotic syndrome and the risk of subsequent recurrent thromboembolism. , 2016, Thrombosis research.

[5]  M. Prins,et al.  The Impact of Residual Thrombosis on the Long-Term Outcome of Patients with Deep Venous Thrombosis Treated with Conventional Anticoagulation , 2015, Seminars in Thrombosis & Hemostasis.

[6]  M. Prins,et al.  Residual vein thrombosis and the risk of subsequent serious complications. , 2015, Thrombosis research.

[7]  G. Raskob,et al.  Thrombosis: a major contributor to global disease burden. , 2014, Thrombosis research.

[8]  G. Raskob,et al.  Thrombosis: A major contributor to global disease burden , 2014, Thrombosis and Haemostasis.

[9]  J. Douketis,et al.  Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis , 2013, Thrombosis and Haemostasis.

[10]  P. Prandoni,et al.  Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism , 2013, Thrombosis and Haemostasis.

[11]  R. Hull,et al.  Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. , 2011, The American journal of medicine.

[12]  P. Wells,et al.  Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism , 2010, Annals of Internal Medicine.

[13]  M. Prins,et al.  Quality of oral anticoagulant treatment and risk of subsequent recurrent thromboembolism in patients with deep vein thrombosis , 2007, Journal of thrombosis and haemostasis : JTH.

[14]  Paolo Prandoni,et al.  The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. , 2007, Haematologica.

[15]  A. Forster,et al.  Effect of study setting on anticoagulation control: a systematic review and metaregression. , 2006, Chest.

[16]  M. Prins,et al.  Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome , 2005, Journal of thrombosis and haemostasis : JTH.

[17]  T. Baglin,et al.  Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study , 2003, The Lancet.

[18]  M Gent,et al.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.

[19]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[20]  Olle Linder,et al.  A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism , 1995 .

[21]  K. Schulman,et al.  Cost-effectiveness analyses. , 1995, The New England journal of medicine.

[22]  S. Schulman,et al.  A Comparison of Six Weeks With Six Months of Oral Anticoagulant Therapy After a First Episode of Venous Thromboembolism , 1996 .

[23]  P Prandoni,et al.  A Simple Ultrasound Approach for Detection of Recurrent Proximal‐Vein Thrombosis , 1993, Circulation.